Moderate to severe Traumatic Brain Injury (TBI) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Moderate to severe Traumatic Brain Injury (TBI) Market Outlook

Thelansis’s “Moderate to severe Traumatic Brain Injury (TBI) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Moderate to severe Traumatic Brain Injury treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Moderate to severe Traumatic Brain Injury (TBI) Overview

Traumatic Brain Injury (TBI) is a disruption in the brain's normal functioning caused by physical impact to the head, such as a blow, bump, or jolt, or when an object penetrates the skull and enters the brain tissue. Clinical signs indicating an alteration in normal brain function include loss of consciousness or decreased consciousness, memory loss (amnesia) for events before or after the injury, focal neurological deficits like muscle weakness or loss of vision, and changes in mental state such as disorientation or difficulty concentrating. The frontal and temporal areas of the brain are primarily affected. Mild TBI, also known as brain concussion, has gained significant attention due to its potential adverse neuropsychological outcomes in civilian populations (e.g., athletes in contact sports) and military personnel. Moderate to severe TBI is a major cause of injury-related death and disability. TBI symptoms can range from mild to severe, depending on the extent of brain damage. Mild cases may temporarily alter mental state or consciousness, while severe cases can lead to prolonged unconsciousness, coma, or even death. There are two main types of head injuries: Penetrating TBI, which occurs when an object pierces the skull and damages a specific area of the brain, and non-penetrating TBI, caused by a strong external force that moves the brain within the skull. Causes of non-penetrating TBI include falls, motor vehicle accidents, sports injuries, blast injuries, and being struck by an object. Clinical features of TBI may include prolonged coma, headache, nausea, aphasia (language difficulties), seizures, amnesia, and behavioral abnormalities such as aggression and anxiety. These symptoms can occur within seconds to minutes after the injury and may persist for months or years. The severity of TBI is evaluated using measures such as level of consciousness (LOC), altered mental status (AMS), post-traumatic amnesia (PTA), and the Glasgow Coma Scale (GCS). TBI causes damage to neuronal tissues, which can be classified into two categories: primary injury, directly caused by the mechanical forces during the initial insult, and secondary injury, which refers to further tissue and cellular damage after the primary insult. The differential diagnosis for TBI includes stroke, spontaneous acute subdural hematoma, Alzheimer's disease, cerebral aneurysms, frontal lobe syndrome, and hydrocephalus. TBI is a significant cause of death and disability among children and young adults in the United States.

• It is estimated that 1.5 million Americans sustain a TBI yearly, resulting in approximately 230,000 hospitalizations, 50,000 deaths, and 80,000 to 90,000 cases of long-term disability.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2022-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: